Microsatellite status and adjuvant chemotherapy in patients with stage II colon cancer

Current Colorectal Cancer Reports

Volumn 6, Issue 3, 2010, Pages 148-157

  Bachet, Jean Baptiste ^b,c   Laurent Puig, Pierre ^d,e,f   De Gramont, Aimery ^a,b   André, Thierry ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c University of Versailles Saint Quentin en Yvelines   (France)

^d INSERM   (France)

^e UFR des Saints Pères   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Adjuvant chemotherapy; Colon cancer; Microsatellite instability (MSI); Predictive factor; Prognosis; Stage II; Survival

Indexed keywords

FLUOROPYRIMIDINE; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; DRUG TREATMENT FAILURE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; REVIEW;

EID: 79952732508     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-010-0054-1     Document Type: Review

References (51)

1. Ferlay J, Autier P, Boniol M, et al.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Gatta G, Capocaccia R, Sant M, et al.: Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut 2000, 47:533-538.
3. Tazi MA, Faivre J, Lejeune C, et al.: Performances du test Hemoccult dans le dépistage des cancers et des adénomes colorectaux. Résultats de cinq campagnes de dépistage en Saône-et-Loire. Gastroenterol Clin Biol 2004, 23:575-580.
4. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358. (Pubitemid 20042739)
5. André T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116, This article reports the final results of the MOSAIC study, with a subgroup analysis of patients with stage II colon cancer.
6. Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and how much? J Clin Oncol 2004, 22:1797-1806. (Pubitemid 41095169)
7. QUASAR Collaborative Group: Adjuvant versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029, This article reports that the use of fluoropyrimidine adjuvant chemotherapy in patients with stage II colon cancer is associated with a 3.6% reduction in the relative risk of death at 5 years.
8. Weitz J, Koch M, Debus J, et al.: Colorectal cancer. Lancet 2005, 365:153-165. (Pubitemid 40091806)
9. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal pathogenesis. Gastroenterology 2008, 135:1079-1099, This is a thorough and insightful review that describes the molecular pathways involved in colorectal carcinogenesis.
10. Haydon AMM, Jass JR: Emerging pathways in colorectal-cancer development. Lancet Oncol 2002, 3:83-88. (Pubitemid 34162978)
11. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257. (Pubitemid 28521189)
12. Umar A, Boland CR, Terdiman JP, et al.: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268. (Pubitemid 38256271)
13. Cunningham JM, Christensen ER, Tester DJ, et al.: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998, 58:3455-3460. (Pubitemid 28371090)
14. Tejpar S, Bosman F, Delorenzi M, et al.: Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009, 27(15S):4001, This large study highlighted MSI phenotype as a major prognostic factor in stage II colon cancer. The abstract and oral presentation from the 2009 American Society of Clinical Oncology meeting were followed by a recent publication showing that MSI phenotype is a prognostic factor in stage II and III colon cancers
15. (Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474).
16. Barault L, Charon-Barra C, Jooste V, et al.: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008, 68:8541-8546.
17. Kohonen-Corish MRJ, Daniel JJ, Chan C, et al.: Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005, 23:2318-2324. (Pubitemid 46218724)
18. Halford S, Sasieni P, Rowan A, et al.: Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002, 62:53-57. (Pubitemid 34073985)
19. Vasen HFA, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-1456. (Pubitemid 29258894)
20. Thibodeau SN, French AJ, Cunningham JM, et al.: Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998, 58:1713-1718. (Pubitemid 28215098)
21. Ward R, Meagher A, Tomlinson I, et al.: Microsatellite and the clinicopathological features of sporadic colorectal cancer. Gut 2001, 48:821-829. (Pubitemid 32476985)
22. Young J, Simms LA, Biden KG, et al.: Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001, 159:2107-2116. (Pubitemid 33104265)
23. Lothe RA, Peltomäki P, Meling GI, et al.: Genomic instability in colorectal cancer: relationship to clinicopathological variables and familial history. Cancer Res 1993, 53:5849-5852. (Pubitemid 24006146)
24. Lanza G, Gafà R, Santini A, et al.: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006, 24:2359-2367. (Pubitemid 46630668)
25. Buhard O, Cattaneo F, Wong YF, et al.: Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 2006, 24:241-251. (Pubitemid 46622053)
26. Hampel H, Frankel WL, Martin E, et al.: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-5788.
27. Chapusot C, Martin L, Laurent-Puig P, et al.: What is the best way to assess microsatellite instability status in colorectal cancer ? Am J Surg Pathol 2004, 28:1553-1559.
28. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257. (Pubitemid 36859476)
29. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal prognosis. J Clin Oncol 2005, 23:609-618. (Pubitemid 46224239)
30. Sinicrope FA, Rego RL, Halling KC, et al.: Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006, 131:729-737. (Pubitemid 44307064)
31. Sargent DJ, Marsoni S, Thibodeau SN, et al.: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008, 26 (15S):4008.
32. Parc Y, Gueroult S, Mourra N, et al.: Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004, 53:371-375. (Pubitemid 38241332)
33. Kim GP, Colangelo LH, Wieand HS, et al.: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007, 25:767-772. (Pubitemid 350002875)
34. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206. (Pubitemid 32319494)
35. Barratt PL, Seymour MT, Stenning SP, et al.: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002, 360:1381-1391. (Pubitemid 35341303)
36. Schwitalle Y, Kloor M, Eiermann S, et al.: Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutations carriers. Gastroenterology 2008, 134:988-997, This article proves that the MSI-induced generation of truncated immunogenic peptides stimulates the antitumor response that probably plays a large role in the better prognosis of patients with MSI tumor.
37. Arnold CN, Goel A, Bolan CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003, 106:66-73. (Pubitemid 36750389)
38. Tajima A, Hess MT, Cabrera BL, et al.: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127:1678-1684. (Pubitemid 39575846)
39. Hemminki A, Mecklin JP, Järvinen H, et al.: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921-928.
40. Des Guetz G, Schischmanoff O, Nicolas P, et al.: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009, 45:1890-1896.
41. Chua W, Goldstein D, Lee CK, et al.: Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009, 101:998-1004.
42. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al.: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2009 Oct 15 (Epub ahead of print), This retrospective study was the first to report that a combination of oxaliplatin and 5-FU improved relapse-free survival compared with 5-FU alone in patients with MSI stage III tumors.
43. Bertagnolli MM, Niedzwiecki D, Compton CC, et al.: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol 2009, 27:1814-1821.
44. Benson AB 3rd, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419. (Pubitemid 41103700)
45. André T, Sargent D, Tabernero J, et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006, 13:887-898. (Pubitemid 43727375)
46. Roth AD, Tejpar S, Yan P, et al.: Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009, 27(15S):4002.
47. Kerr D, Gray R, Quirke P, et al.: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 27(15S):4000, This study reports the promising results of the 12-gene colon cancer recurrence score to identify high-risk stage II colon cancers.
48. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327.
49. Gill S, Loprinzi C, Kennecke H, et al.: Analysis of prognostic web-based models for stage II and III colon cancer: a population-based validation of Numeracy and Adjuvant! Online. J Clin Oncol 2009, 27(15S):4044.
50. Pagès F, Kirilovsky A, Mlecnik B, et al.: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951, This study brings to light growing evidence for the prognostic role of the extent of intratumoral immune reaction in colon cancer.
51. Sakamoto J, Ohashi Y, Hamada C, et al.; Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Meta-Analysis Group in Cancer: Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004, 22:484-492.